Peptron’s PT105, a sustained-release Leuprolide, established the bioequivalence with Takeda’s Leuplin
Peptron's PT105, a sustained-release Leuprolide, established the bioequivalence with Takeda's Leuplin. Global and regional deal to be initiated. PT105 represents Korea's first commercialized generic drug of Leuplin, applied with SmartDepot technology. Development of 3- and 6-month generic Leuprolide for the global market soon to be initiated. DAEJEON, South Korea,...
Everest Medicines Announces Major Regulatory Updates in Taiwan and South Korea for Nefecon for the Treatment of Primary IgA Nephropathy
-- Taiwan Food and Drug Administration grants Accelerated Approval Designation (AAD) to Nefecon -- -- Ministry of Food and Drug Safety in South Korea grants ODD to Nefecon -- -- Nefecon is a first-in-disease treatment for IgAN patients and has been approved in U.S. and E.U. -- SHANGHAI, Nov. 28, 2022 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK), a biopharmaceutical...
Innovent Announced Clinical Data of Multiple Trials Will be Presented at the 2022 ESMO-IO and ASH Annual Meetings
ROCKVILLE, Md. and SUZHOU, China, Nov. 28, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, today announced that clinical data from multiple trials in relation to TYVYT® (sintilimab injection), olverembatinib (BCL-ABL TIK), IBI188(anti-CD47 monoclonal antibody),...
Lyvgen Announces Phase 2 Clinical Collaboration with Bristol Myers Squibb to Evaluate LVGN7409 in Combination with Nivolumab in Non-Small Cell Lung Cancer Patients
LVGN7409 is a next generation CD40 agonistic antibody; Nivolumab is a PD-1 checkpoint inhibitor; docetaxel is an anti-tubulin chemotherapy agent Combination study to begin in 1st half 2023 SHANGHAI and SUZHOU, China, Nov. 28, 2022 /PRNewswire/ -- Lyvgen Biopharma, a leading innovative global biotech company dedicated to discovering, developing and commercializing...
Fovia Ai to Showcase AI Visualization Integrations at IAIP Exhibit, RSNA 2022
Fovia Ai Provides Efficiency Gains for Radiology Workflows CHICAGO, Nov. 27, 2022 /PRNewswire/ -- Fovia Ai, Inc., a subsidiary of Fovia, Inc., a world leader in advanced visualization for nearly two decades and a preeminent provider of zero-footprint, cloud-based imaging SDKs, today announced that it will be showcasing AI visualization, navigation and seamless integrations of AI that provide...
New study on deep learning technology for improving MRI image quality published in European Radiology
SwiftMR™, an AI-powered MRI reconstruction solution from AIRS Medical proved its performance for enhancing the image quality of 3D high-resolution MRI SEOUL, South Korea, Nov. 25, 2022 /PRNewswire/ -- A recent study published in European Radiology demonstrated that SwiftMR, an AI-powered MRI reconstruction solution from AIRS Medical, successfully denoises 3D MR images and improves its image quality by using routine clinical...
VUNO Showcases their AI Solutions and Research Results at RSNA 2022
SEOUL, South Korea, Nov. 25, 2022 /PRNewswire/ -- VUNO Inc., a leading South Korean artificial intelligence (AI) developer, announced that it will participate in the Radiological Society of North America 2022 (RSNA 2022). This year, VUNO will focus on highlighting how their breakthrough AI technology drives real world clinical value across radiological workflows and how their solutions contribute to...
Neurophet, to participate in the Radiological Society of North America RSNA 2022
̵ Introducing 4 products at the booth including the main product Neurophet AQUA ̵ Conducting in-depth discussions jointly team members from R&D and cooperation with several global companies SEOUL, South Korea, Nov. 25, 2022 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for brain disease, announced on the 25th that Neurophet...
Chemotherapy may be completed within 8 days with two doses of Polytaxel, an innovative anticancer drug from South Korea’s biotech firm
Polytaxel, a novel pain-free anticancer drug, may not require break periods A new standard of care, more convenient than docetaxel, is suggested Hyundai Bioscience to enter clinical trial on pancreatic cancer in Australia Patient-centered chemotherapy to enable outpatients to live normal lives SEOUL, South Korea , Nov. 25, 2022 /PRNewswire/ --...
Concord Medical Schedules 2022 Annual Meeting of Shareholders
BEIJING, Nov. 25, 2022 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced that it will hold its 2022 annual general...
